|Systematic (IUPAC) name|
|ATC code||N07CA03 (WHO)|
|Molar mass||404.495[[Script error: No such module "String".]]|
Flunarizine is a drug classified as a calcium channel blocker. Flunarizine is a non-selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia. Flunarizine was discovered at Janssen Pharmaceutica in 1967.
- Sibelium by Janssen Pharmaceutica.
- Van Nueten JM, Janssen PA., Comparative study of the effects of flunarizine and cinnarizine on smooth muscles and cardiac tissues, Arch Int Pharmacodyn Ther. 1973 Jul;204(1):37-55.
- Amery WK., Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine, Headache. 1983 Mar;23(2):70-4.
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
|35px||This drug article relating to the nervous system is a stub. You can help ssf by expanding it.|